Datasheet for ABIN988002

IL29 Protein

Go to Product page

Overview

Quantity:	1 mg
Target:	IL29
Origin:	Human
Source:	Escherichia coli (E. coli)
Biological Activity:	Active

Product Details

Sequence:	GPVPTSKPTT TGKGCHIGRF KSLSPQELAS FKKARDALEE SLKLKNWSCS SPVFPGNWDL RLLQVRERPV ALEAELALTL KVLEAAAGPA LEDVLDQPLH TLHHILSQLQ ACIQPQPTAG PRPRGRLHHW LHRLQEAPKK ESAGCLEASV TFNLFRLLTR DLKYVADGNL CLRTSTHPES
Characteristics:	Fully biologically active when compared to standard. The ED50 is determined in an anti-viral assay using human HepG2 cells infected with encephalomyocarditis is typically 1-5 ng/ml,corresponding to a specific activity of > 2.0×105 units/mg.
Purity:	> 97 % by SDS-PAGE and HPLC analyses.
Endotoxin Level:	Level Less than 1EU/μg of rHuIFN-lambda1 as determined by LAL method

Target Details

Target:	IL29
Alternative Name:	Interferon-Lambda1 (IFN-Lambda1) (IL29 Products)
Background:	IL-28A, IL-28B, and IL-29, also named interferon-lambda2 (IFN-lambda2), IFN-lambda3, and IFN-lambda1, respectively, are newly identified class II cytokine receptor ligands that are distantly

Target Details

	related to members of the IL-10 family (11-13% aa sequence identity) and the type I IFN family (15-19% aa sequence identity). The expression of IL-28A, B, and IL-29 is induced by virus infection or double-stranded RNA. All three cytokines exert bioactivities that overlap those of type I IFNs, including antiviral activity and up-regulation of MHC class I antigen expression. The three proteins signal through the same heterodimeric receptor complex that is composed of the IL-10 receptor beta (IL-10 Rbeta) and a novel IL-28 receptor alpha (IL-28 Ralpha, also known as IFN-lambdaR1). Ligand binding to the receptor complex induces Jak kinase activation and STAT1 and STAT2 tyrosine phosphorylation. Synonym: Interferon-lambda1 (IFN-lambda1), Human. Formulation: Lyophilized from a 0.2µm filtered concentrated solution in 20mM PB, pH 7.4, 130mM NaCl.
Molecular Weight:	Approximately 19.8 kDa, a single non-glycosylated polypeptide chain containing 181 amino acids.

Application Details

Restrictions:	For Research Use only

Handling

Format:	Lyophilized
Reconstitution:	We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at < -20 °C. Further dilutions should be made in appropriate buffered solutions.
Storage:	4 °C